DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
? Autolus Therapeutics
NASDAQ: AUTL
Report Analisi Approfondita | AUCATZYL obe-cel • CD19 CAR-T • B-ALL FDA Approved • Lupus Nephritis Phase 1 • MS Pipeline
Current Price
$1.41
Analyst Target
$9.12
Upside Potential
+545%
Market Cap
$375M
? Andamento Prezzo 6 Mesi (Maggio – Novembre 2025)
Prezzo Massimo
$4.12
Prezzo Minimo
$1.11
Range 6M
$3.01 (271%)
Volatilità
ULTRA ALTA
? Executive Summary
Autolus Therapeutics è una biotech commerciale specializzata in CAR-T cell therapy. Il suo principale asset AUCATZYL (obe-cel) è il primo CD19 CAR-T therapy approvato negli USA, UK e EU per B-ALL relapsed/refractory, con straordinario potenziale di espansione in lupus nephritis e multiple sclerosis.
? CATALIZZATORE IMMINENTE – DOMANI:
- Novembre 12, 2025 (DOMANI @ 8:30 AM EST): Q3 2025 Earnings Report LIVE + Conference Call
- Late 2025: Full data lupus nephritis Phase 1 CARLYSLE trial (3 pazienti con complete renal response)
- Year-End 2025: Prima dose MS Phase 1 (first patient dosing progressive multiple sclerosis)
- Phase 2 Lupus: Pivotal trial initiato by year-end 2025
Profilo Aziendale
- Market Cap: $375 milioni (micro-cap growth)
- Cash Position: $454.3M (June 30, 2025) – Molto forte
- Lead Product: AUCATZYL (obe-cel) – CD19 CAR-T, FDA-approved B-ALL
- Revenue TTM: $30.18M – Stage commerciale iniziale
- Focus Terapeutico: CAR-T oncology + expansion in autoimmune (lupus, MS)
AUCATZYL: Franchise Multi-Indicazione
- B-ALL Approved (USA/UK/EU): Commerciale, 60 centri USA entro fine 2025
- Lupus Nephritis Phase 1: 3 pazienti con complete renal response a month 3 – PROMETTENTE
- Progressive MS Phase 1: First patient dosing atteso year-end 2025
- Dual CD19/CD22 Targeting: AUTO6 candidate per escape prevention
⚡ Catalizzatori Dettaglio & Timeline
1. Q3 2025 Earnings – DOMANI (Nov 12 @ 8:30 AM EST)
CATALIZZATORE IMMEDIATO. Autolus riporterà Q3 2025 risultati finanziari + commercial update AUCATZYL uptake.
- Q2 2025 Revenue: $20.9M (incremento sequenziale da Q1 $9M)
- H1 2025 Total: $29.9M (tracking towards $80-120M run-rate)
- Expected Topics: B-ALL uptake trajectory, lupus data, MS initiation timing
- Market Impact: Beat estimates potrebbe triggare +10-20% move
2. Lupus Nephritis Phase 1 Data – H2 2025
BREAKTHROUGH POTENTIAL. CARLYSLE trial mostra 3/3 pazienti con complete renal response.
- Current Data: 3 SLE pazienti, complete renal response at month 3 – STRAORDINARIO
- Full Data Timing: H2 2025 medical conference presentation
- Phase 2 Pivotal: Enrollment partirà year-end 2025
- Market Opportunity: Lupus nephritis è indicazione grave con unmet need $5B+ TAM
- Stock Impact: Se dati rimangono positive, +50-100% move possibile
3. Progressive MS Phase 1 – Year-End 2025
MS EXPANSION. First patient dosing atteso entro fine 2025.
- Indication: Progressive multiple sclerosis – unmet need, large market $8-10B+ TAM
- Mechanism: B-cell depletion via CD19 CAR-T – validated in autoimmunity
- Competitive Advantage: Autolus è SOLO CAR-T in development per autoimmune
? Financial Position & Sustainability
Fortress Balance Sheet
- Cash & Equivalents: $454.3M (June 30, 2025)
- No Debt: Clean balance sheet
- Burn Rate: ~$60-80M per quarter (R&D + commercial)
- Cash Runway: 2+ years fully funded without revenue
Revenue Trajectory
- Q1 2025: $9.0M (AUCATZYL commercial launch)
- Q2 2025: $20.9M (+132% sequential) – Acceleration
- Q3 2025: Expected $20-25M (seasonal patterns)
- 2025 Full-Year: $70-80M potential (first full commercial year)
- Peak Sales B-ALL Alone: $200-300M+ (as market penetrates)
Upside Scenarios
- Lupus Approval: +$400-600M peak sales opportunity
- MS Success: +$1-2B peak sales (larger market)
- Multi-Indication: Total CAR-T franchise could reach $2-3B+ peak sales
⚠️ Risk & Opportunity
? Downside Risks
- Q3 Earnings Miss: Se revenue guidance delude
- B-ALL Uptake Slow: Commercial execution challenges
- Lupus Data Setback: Se Phase 1 results deludono
- MS Safety: If Phase 1 shows safety issues
- Dilution Risk: Potrebbe necesario capital raise
? Upside Opportunities
- Q3 Beat Tomorrow: +10-20% move if upside surprise
- Lupus Phase 2 Launch: Potential blockbuster indication
- MS Phase 1 Success: +50-100% move potential per patient dosing
- Multi-Indication Franchise: $2-3B peak sales TAM
- M&A Target: Big pharma acquisition interest at $5-10/share
- Analyst Upgrades: Currently Strong Buy @ $9.12 target
? Valuation Scenarios & Price Targets
Bull Case (Multi-Indication Success)
Analyst Target (12M)
$9.12
+545% upside
Bull Case (2026)
$12-15
+750% to +960%
Base Case
$5-7
+254% to +396%
Bear Case (Both Catalysts Failure)
Bear Case
$0.80-1.00
-43% to -29% downside
? Trading Strategy “Catalyst Run-Up”
Two Major Catalysts – ULTRA HIGH VOLATILITY
Setup Ideale Micro-Cap Biotech:
- ✅ Catalyst DOMANI (Q3 earnings)
- ✅ Analyst target $9.12 vs current $1.41 = 545% upside
- ✅ Multiple value inflection points (earnings, lupus data, MS initiation)
- ✅ Strong cash position elimina dilution risk short-term
- ✅ Micro-cap = 100%+ moves not-rare su positive catalysts
Entry Strategy
- Pre-Earnings Zone: $1.30-1.50 (accumulation)
- If Earnings Beat: Breakout to $1.80-2.00+
- Lupus Data Phase 2 Initiation: Target $5-7 medium-term
- MS Initiation Year-End: Potential $7-10 target
✅ Investment Recommendation
Rating: STRONG BUY – ULTRA VOLATILE
Key Reasons
- Earnings Tomorrow: Immediate catalyst 8:30 AM EST
- Multi-Catalyst Setup: Earnings + lupus + MS = 3 shots 2025-2026
- 545% Upside: Analyst target $9.12 (Strong Buy consensus)
- Fortress Balance: $454M cash, no debt
- Breakthrough Therapy: AUCATZYL in lupus – unmet need indication
- Micro-Cap Volatility: +100%+ moves realistic per catalyst
Price Targets
- Immediate (Post-Earnings): $1.80-2.20 (+27-56%)
- 6-Month (Lupus Phase 2): $5-7 (+254-396%)
- 12-Month (MS + multi-indication): $9-12+ (+545-750%)
⏰ Earnings Call DOMANI – 12 Nov 2025 @ 8:30 AM EST
Segui LIVE Autolus Q3 earnings announcement + conference call
Accedi Investor Relations →? Autolus Therapeutics
NASDAQ: AUTL
Complete Analysis Report | AUCATZYL obe-cel • CD19 CAR-T • B-ALL FDA Approved • Lupus Nephritis Phase 1 • MS Pipeline
Current Price
$1.41
Analyst Target
$9.12
Upside Potential
+545%
Market Cap
$375M
? Price Performance 6 Months (May – November 2025)
Peak Price
$4.12
Lowest Price
$1.11
6M Range
$3.01 (271%)
Volatility
ULTRA HIGH
? Executive Summary
Autolus Therapeutics is a commercial-stage biotech specializing in CAR-T cell therapy. Its lead asset AUCATZYL (obe-cel) is the first CD19 CAR-T therapy approved in USA, UK, and EU for relapsed/refractory B-ALL, with extraordinary potential for expansion into lupus nephritis and multiple sclerosis.
? IMMEDIATE CATALYST – TOMORROW:
- November 12, 2025 (TOMORROW @ 8:30 AM EST): Q3 2025 Earnings Report LIVE + Conference Call
- H2 2025: Full data lupus nephritis Phase 1 CARLYSLE trial
- Year-End 2025: First patient dosing MS Phase 1
- Phase 2 Lupus: Pivotal trial initiation expected by year-end
Company Profile
- Market Cap: $375 million (micro-cap biotech)
- Cash Position: $454.3M (June 30, 2025) – Very strong
- Lead Product: AUCATZYL (obe-cel) – CD19 CAR-T, FDA-approved B-ALL
- Revenue TTM: $30.18M – Early commercial stage
- Focus: CAR-T oncology + autoimmune expansion (lupus, MS)
AUCATZYL: Multi-Indication Franchise
- B-ALL Approved (USA/UK/EU): Commercial, 60 US centers by end 2025
- Lupus Nephritis Phase 1: 3 patients with complete renal response at month 3 – PROMISING
- Progressive MS Phase 1: First patient dosing expected year-end 2025
- Dual CD19/CD22 Targeting: AUTO6 candidate for escape prevention
⚡ Catalysts Detail & Timeline
1. Q3 2025 Earnings – TOMORROW (Nov 12 @ 8:30 AM EST)
IMMEDIATE CATALYST. Autolus will report Q3 2025 financial results + AUCATZYL commercial update.
- Q2 2025 Revenue: $20.9M (sequential increase from Q1 $9M)
- H1 2025 Total: $29.9M (tracking towards $80-120M run-rate)
- Expected Topics: B-ALL uptake trajectory, lupus data, MS initiation timing
- Market Impact: Beat estimates could trigger +10-20% move
2. Lupus Nephritis Phase 1 Data – H2 2025
BREAKTHROUGH POTENTIAL. CARLYSLE trial shows 3/3 patients with complete renal response.
- Current Data: 3 SLE patients, complete renal response at month 3 – EXTRAORDINARY
- Full Data Timing: H2 2025 medical conference presentation
- Phase 2 Pivotal: Enrollment to start year-end 2025
- Market Opportunity: Lupus nephritis is severe indication with $5B+ unmet need TAM
- Stock Impact: If data remains positive, +50-100% move possible
3. Progressive MS Phase 1 – Year-End 2025
MS EXPANSION. First patient dosing expected by year-end.
- Indication: Progressive multiple sclerosis – $8-10B+ TAM
- Mechanism: B-cell depletion via CD19 CAR-T – validated in autoimmunity
- Competitive Advantage: Autolus ONLY CAR-T in development for autoimmune
? Financial Position & Sustainability
Fortress Balance Sheet
- Cash & Equivalents: $454.3M (June 30, 2025)
- No Debt: Clean balance sheet
- Burn Rate: ~$60-80M per quarter (R&D + commercial)
- Cash Runway: 2+ years fully funded
Revenue Trajectory
- Q1 2025: $9.0M (AUCATZYL commercial launch)
- Q2 2025: $20.9M (+132% sequential)
- 2025 Full-Year: $70-80M potential
- Peak Sales B-ALL: $200-300M+ opportunity
Multi-Indication Upside
- Lupus Approval: +$400-600M peak sales
- MS Success: +$1-2B peak sales
- Total CAR-T Franchise: $2-3B+ peak sales potential
⚠️ Risk & Opportunity
? Downside Risks
- Q3 Earnings Miss: If revenue disappoints
- B-ALL Slow Uptake: Commercial execution challenges
- Lupus Data Setback: If Phase 1 results disappoint
- MS Safety Issues: If Phase 1 shows safety concerns
- Dilution Risk: Potential capital raise needed
? Upside Opportunities
- Q3 Beat Tomorrow: +10-20% move if upside surprise
- Lupus Phase 2 Launch: Potential blockbuster indication
- MS Phase 1 Success: +50-100% move potential
- Multi-Indication Franchise: $2-3B peak sales
- M&A Target: Big pharma acquisition at $5-10/share
- Analyst Upgrades: Strong Buy @ $9.12 target
? Valuation Scenarios
Bull Case (Multi-Indication Success)
Analyst Target (12M)
$9.12
+545% upside
Bull Case (2026)
$12-15
+750% to +960%
Base Case
$5-7
+254% to +396%
Bear Case
Bear Case
$0.80-1.00
-43% to -29% downside
? Trading Strategy
Micro-Cap Biotech Setup – ULTRA HIGH VOLATILITY:
- ✅ Catalyst TOMORROW (Q3 earnings)
- ✅ Analyst target $9.12 vs current $1.41 = 545% upside
- ✅ Multiple value inflection points (earnings, lupus, MS)
- ✅ Strong cash eliminates dilution risk near-term
- ✅ Micro-cap = 100%+ moves common on positive catalysts
Entry Strategy
- Pre-Earnings Zone: $1.30-1.50
- If Earnings Beat: Breakout to $1.80-2.00+
- Lupus Phase 2 Initiation: Target $5-7
- MS Initiation Year-End: Target $7-10
✅ Investment Recommendation
Rating: STRONG BUY – ULTRA VOLATILE
Key Reasons
- Earnings Tomorrow: Immediate catalyst
- Multi-Catalyst Setup: Earnings + lupus + MS
- 545% Upside: Analyst target $9.12
- Fortress Balance: $454M cash, no debt
- Breakthrough Therapy: AUCATZYL in lupus
- Micro-Cap Volatility: 100%+ moves realistic
Price Targets
- Immediate (Post-Earnings): $1.80-2.20 (+27-56%)
- 6-Month (Lupus Phase 2): $5-7 (+254-396%)
- 12-Month (MS + multi-indication): $9-12+ (+545-750%)
⏰ Earnings Call TOMORROW – 12 Nov 2025 @ 8:30 AM EST
Follow LIVE Autolus Q3 earnings announcement + conference call
Access Investor Relations →